Advertisement
News
Advertisement

Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly

Thu, 05/26/2011 - 4:45am

 

Amylin Pharmaceuticals, Inc. today announced that the United States District Court for the Southern District of California issued a temporary restraining order (TRO) against Eli Lilly and Company relating to its litigation with respect to the Amylin / Lilly diabetes collaboration agreement.

The U.S. District Court restrained Lilly from proceeding with its plans to use the same sales force to sell both exenatide and Boehringer Ingelheim GmbH's competitive linagliptin. The court also enjoined Lilly from disclosing any confidential information about exenatide to any of its sales representatives or employees participating in the marketing, promotion or sale of linagliptin.

The complete order is being filed today on Amylin's Current Report on Form 8-K with the Securities and Exchange Commission.

In 2002, Amylin entered an alliance with Lilly for the global development and commercialization of exenatide, a medicine indicated as a first line treatment for type 2 diabetes that is currently marketed as BYETTA (exenatide) injection. Exenatide is also the active ingredient in BYDUREONT (exenatide extended-release for injectable suspension), a once-weekly version currently under review by the FDA.

 

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading